Clarivate

JUNE 29, 2023

OpenAI’s launch of ChatGPT on March 14 heralds a new era of artificial intelligence that will have profound implications for society, including the life science and healthcare industries. billion (read our recent report on biopharma dealmaking to learn more about activity in this space).

Patients 98

Patients Safety Healthcare Healthcare 98

PM360

JUNE 24, 2024

But the role of AI in healthcare will go beyond this. healthcare, with its 17% share of GDP, is “the most disruptable industry in the world,” and “the first big carcass that AI is going to start to feed on.” It provides guidance and acts as a safety net for prescribers. And there’s more to come.

Healthcare 52

Healthcare Healthcare Patients Side effects 52

Clarivate

OCTOBER 17, 2024

Pharma executives are keen to see clinical data, preclinical studies, and real-world evidence that support claims about the efficacy and safety of the offering. Moreover, having a clear insight into how the asset will navigate the regulatory landscape increases the likelihood of a successful partnership or investment.

Pharma 59

Pharma Competition Marketing Healthcare 59

Clarivate

JULY 31, 2023

Following the acquisition of Dialog Solutions as part of the ProQuest M&A in December 2021, Dialog Solutions products and services will be folded into the Clarivate portfolio of offerings for Life Sciences & Healthcare. To learn more about the Dialog platform, visit: here.

Healthcare 52

Healthcare Healthcare Safety Competition 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

An international team of scientific, regulatory, and safety and compliance (GxP) specialists, PharmaLex is based in Germany. The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product.

Biopharma 52

Biopharma Manufacturing Pharmaceutical manufacturing Marketing 52

Pharma Marketing Network

MARCH 25, 2022

With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. If caregiving is positioned as an essential service and caregivers are counted among healthcare’s front-line service providers, 4 does it follow caregivers are a viable healthcare vertical?

Pharma 98

Pharma Education Training Transportation 98

European Pharmaceutical Review

DECEMBER 21, 2022

Despite the tidal wave of renewed interest in psychedelic therapies, there is still much to be learned about them, including their precise mechanisms of action, their long- and short-term safety profiles, the durability of their effect, and their adverse effects—which can be severe. Medicines and Healthcare products Regulatory Agency.

Food and Drug Administration 119

Food and Drug Administration Medicine Food Government 119

PharmaTech

JANUARY 4, 2024

Eurofins acknowledges the significance of Cell and Gene Therapies, particularly Autologous Cell Therapies , in the healthcare industry. Recognizing the urgency associated with short shelf-life products, Eurofins BioPharma Product Testing has developed a comprehensive set of services to address the need for swift and reliable testing.

Biopharma 40

Biopharma Safety Healthcare Healthcare 40

pharmaphorum

SEPTEMBER 12, 2022

Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. Knowledge can change the course of healthcare for all and alter the course of care for individuals in need. Tailored oncology.

Patients 105

Patients Medicine FDA Healthcare 105

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. The entire premise was that because biosimilars were so new, and there was not a lot of information on the safety and efficacy of those products, customers should be a bit leery prior to jumping on the biosimilar bandwagon. specialty division of Intas Pharmaceuticals, Ltd.,

Competition 98

Competition Marketing Manufacturing Biopharma 98

PM360

OCTOBER 8, 2024

The company is the only pure-bred pharmacovigilance specialist, providing comprehensive, independent pharmacovigilance services as well as advanced tools and technology-powered solutions that address companies’ most complex product safety needs. The business is supported by investment from Stanley Capital Partners.

Leads 52

Leads Safety Biopharma Management 52

pharmaphorum

SEPTEMBER 28, 2022

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset. In recent years, the biopharma market has become progressively complex.

Biopharma 52

Biopharma Side effects Consulting Pharmaceutical products 52

Veeva

JANUARY 30, 2024

Delivering tailored experiences for HCPs in the age of digital engagement When it comes to engaging with healthcare professionals (HCPs), personalization, omnichannel and multichannel strategies are key buzzwords. But what do these really mean, and how can biopharma companies tailor experiences for HCPs and achieve their business objectives?

Biopharma 52

Biopharma Sales Safety Marketing 52

Pharmaceutical Technology

JULY 7, 2022

There is a lot of excitement that we could be at the start of a new era for the biopharmaceutical industry, with the hope of delivering revolutionary healthcare for previously unaddressed diseases finally becoming a reality.

Medicine 98

Medicine Transportation Manufacturing Biopharma 98

Pharmaceutical Representative Training

JANUARY 29, 2025

Biosimilars: The Future of Affordable Biologic Therapies Biologics are some of the most expensive forms of therapy in modern healthcare. However, there are products that can help bridge the affordability gap created by these biologics, while also providing similar efficacy and safety for patient treatment.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

PM360

SEPTEMBER 15, 2022

But battling information asymmetry is one of the best ways to address the ongoing inequities in our healthcare system. But to shift the industry’s approach to healthcare, all stakeholders must move the efforts, attention, and education necessary to find a common ground and ensure that the patients’ interests are always driving development.

Patients 98

Patients Healthcare Healthcare Marketing 98

European Pharmaceutical Review

FEBRUARY 21, 2023

Crucially, January 2023 marked a key moment: the Medicines and Healthcare products Regulatory Agency (MHRA) granted Celadon Pharmaceuticals the first good manufacturing practice (GMP) registration since legalisation in 2018 for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API).

Medicine 132

Medicine Manufacturing Specialization Pharmaceutical 132

European Pharmaceutical Review

DECEMBER 19, 2022

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. References/Endnotes. Biosimilars in the EU.

Medicine 52

Medicine Biopharma Safety Food 52

pharmaphorum

SEPTEMBER 20, 2022

The phase 1/3 ROSALIA study showed that the copycat denosumab matched Amgen’s brand on multiple pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity measures in postmenopausal women with osteoporosis, said Sandoz in a statement. billion TNF inhibitor Enbrel (etanercept) and $2.25

Medicine 52

Medicine Marketing Safety Biopharma 52

PM360

JUNE 24, 2024

This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.

Marketing 52

Marketing Patients Food and Drug Administration Digital Media 52

Pharmaceutical Technology

SEPTEMBER 8, 2022

The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time. Patient monitoring for safety and efficacy. Dispensing of speciality pharmaceuticals and shipping coordination. Prescription refill and renewal.

Specialization 45

Specialization Leads Pharma Side effects 45

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Marketing Physicians Biopharma 52

Clarivate

OCTOBER 25, 2023

Expect some provider practices to research using alternative treatments not subject to price negotiations for their new patients, assuming comparable efficacy, safety, and tolerability (e.g., Providers therefore could find their buy and bill operations are in the red.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

OCTOBER 22, 2024

DANNY SIGURDSON CEO and Founder Courier Health To effectively engage patients and prescribers to improve overall adherence to prescribed medication regimens, biopharma companies first need the visibility and full context of where a patient stands in their treatment journey. Support healthcare providers in a real and personal way.

Education 52

Education Side effects Medical Patients 52

Clarivate

MARCH 17, 2022

How feasible is it to establish a drug’s safety for use in a population that may be unwilling or unable to participate in clinical trials? The health of pregnant people and their fetuses can be compromised if the dose/dosing regimen, safety, and efficacy of treatments used during pregnancy are not established.

Food and Drug Administration 10

Food and Drug Administration Safety FDA Ethics 10

Clarivate

DECEMBER 9, 2021

In this episode of Conversations in Healthcare , leaders from Cigna, Henry Ford Health System and eHI discuss how telehealth can help bridge care gaps. Download our new report at right for latest analysis of telehealth’s potential to address healthcare inequities.

Healthcare 52

Healthcare Healthcare Medicine Doctors 52

Clarivate

MAY 13, 2024

Key takeaways Although growth in commercial and exchange enrollment will blunt some impacts, an increased uninsured rate will lead to increased uncompensated care, adding to cost pressures for health systems, especially safety-net hospitals that will see the highest volume of people cut from Medicaid. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Clarivate

FEBRUARY 28, 2024

Data from a rising tide of sources can empower pharma executive decision making from R&D, clinical studies, health outcomes, drug safety, and market access. CDISC standards cover various aspects of clinical research data, including study design, data collection, data representation, and data exchange.

Healthcare 59

Healthcare Healthcare Electronics Medicine 59

Clarivate

NOVEMBER 13, 2023

The purpose of clinical trials is to understand the efficacy and safety of treatments for the patients who need them. Last year alone the Clarivate COA team conducted over 300 interviews with patients, caregivers or healthcare professionals. The PFDD series will eventually take the place of the PRO Guidance for Industry.

Patients 52

Patients Food and Drug Administration FDA Safety 52

Clarivate

OCTOBER 19, 2023

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

JULY 6, 2023

Precision medicine The biopharma industry is increasingly moving towards a precision medicine approach that enables patients to be treated at an earlier stage of disease for better outcomes. This process provides crucial spatial context to molecular data, enhancing our understanding of diseases and informing clinical decision-making.

Consulting 52

Consulting Medicine Biopharma Patients 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. It gives the FDA greater authority to remove an accelerated approval drug from the market based on poor follow-up safety or efficacy data.

FDA 52

FDA Prescription Medicine Biopharma 52

Medgadget

MARCH 2, 2023

Moreover, due to the different nature of healthy and cancerous tissue, alpha radiation produced by Alpha DaRT sources diffuses about a millimeter into healthy tissue while penetrating at a diameter up to about five millimeters into tumors, providing an automatic safety mechanism.

Manufacturing 82

Manufacturing Leads Patients Medicine 82

Clarivate

NOVEMBER 10, 2022

The purpose of clinical trials is to understand the efficacy and safety of treatments for the patients who need them. In this article, we share how a sponsor partnered with Clarivate to incorporate COAs into clinical trials for alopecia areata. The regulatory landscape around COAs is fast evolving.

Patients 52

Patients Food and Drug Administration FDA Safety 52

Clarivate

MAY 24, 2022

The consortium aims to promote awareness for rare diseases within the healthcare community and general public, address the impending issue of drug availability and improve the quality of life of rare disease patients. Gain access to intelligence on Mainland China’s healthcare market and disease-specific trends. 10] [11] [12].

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

Clarivate

MARCH 14, 2024

Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt. Future research could focus on developing PFAS-free packaging materials that meet regulatory standards without compromising safety. Impending change affords an opportunity for innovation.

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52

Clarivate

MAY 11, 2023

Over the past five years, healthcare leaders in Mainland China have made significant strides in their efforts to reduce lag time in availability of novel drugs versus western markets. CDE also released guidelines on Clinical trial requirements for overseas drugs.

Marketing 52

Marketing Patients Management Insurance 52